A carregar...
Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
BACKGROUND & AIMS: Infigratinib is a pan‐FGFR (fibroblast growth factor receptor) inhibitor that has shown encouraging activity in FGFR‐dependent hepatocellular carcinoma (HCC) models. However, long‐term treatment results in the emergence of resistant colonies. We sought to understand the mechan...
Na minha lista:
| Publicado no: | Liver Int |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894323/ https://ncbi.nlm.nih.gov/pubmed/33179425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14728 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|